The following letter from our CEO, Peter Keeling was published today in the Financial Times
Your article “Piggybacking on US pharma will no longer fly” (The world will need to stop piggybacking on US pharma, September 2) might have mentioned the very different economics at play within precision medicine product portfolios. Recently published US portfolio returns suggest precision medicine drugs are about 25 per cent cheaper to develop and deliver greater clinical outcomes, deserving of value- based pricing. This same analysis suggests that while more needs to be done to invest in patient testing to optimise the return on investment for precision treatment, such testing will probably provide pharma with a strong defence in pricing negotiations. Your article is a good overview of some of the pressures on the pharma C-suites but perhaps should have given more consideration to the shift to precision medicine and the role this will play in delivering more of a balanced value outcome for all.
